The race for no. 3 in obesity drugs just got tougher. At the American Diabetes Association meeting in New Orleans, market leader Eli Lilly & Co. asserted its dominance with data showing its next-generation shot, retatrutide, can help patients lose 30% of their body weight over about two years. Novo Nordisk A/S , the no. 2, said its new Wegovy obesity pill surpassed three million prescriptions. Som...
The race for no. 3 in obesity drugs just got tougher. At the American Diabetes Association meeting in New Orleans, market leader Eli Lilly & Co. asserted its dominance with data showing its next-generation shot, retatrutide, can help patients lose 30% of their body weight over about two years. Novo Nordisk A/S , the no. 2, said its new Wegovy obesity pill surpassed three million prescriptions. Some of the companies looking to challenge the leaders had a tougher time. Boehringer Ingelheim GmbH ’s survodutide was less competitive on weight loss and had high vomiting rates, data showed, sending shares of its Danish biotech licensee Zealand Pharma A/S down as much as 27% on Monday. A Roche Holding AG shot pitched as a gentler alternative lagged a similar drug from Lilly on efficacy, according to Bloomberg Intelligence analysts. Boehringer and Roche, along with AstraZeneca Plc , Pfizer Inc. and Amgen Inc. , are all pitching a future where patients and doctors choose an obesity treatment not only based on potential pounds lost. Convenience, the scale of side effects or better results on the plethora of conditions that accompany excess weight should also inform the choice. “We’ve got to change this from just a race to who can provide that biggest weight-loss number,” Brian Hilberdink , who leads Boehringer’s US human pharma unit, said in an interview. Their problem is that market heavyweights Lilly and Novo are also trying to fill the same niches. Novo is exploring whether its drugs could have a role in the buzzy area of life longevity, Chief Executive Officer Mike Doustdar told Bloomberg on Sunday. With billions of people living with overweight or obesity, it’s unreasonable to think that everyone will be satisfied with a single medicine, Ken Custer , president of Lilly’s cardiometabolic health unit, said in a company press program. “In the years to come we’re going to move from a one-size-fits-all approach,” he added. Read More: Novo CEO Looks Beyond Weight Loss to Longev...
Lordhenrivoton | E+ | Getty Images When people think of how much to save for retirement — and, subsequently, how to spend that money wisely in older age — many worry about the risk of running out of money early. They fear the possibility of overspending. But there's another less-appreciated danger, too, according to financial experts: The risk of underspending one's nest egg. "Overspending is risk...
Lordhenrivoton | E+ | Getty Images When people think of how much to save for retirement — and, subsequently, how to spend that money wisely in older age — many worry about the risk of running out of money early. They fear the possibility of overspending. But there's another less-appreciated danger, too, according to financial experts: The risk of underspending one's nest egg. "Overspending is risky. But underspending is risky too," said Zach Teutsch, a member of CNBC's Financial Advisor Council and founder of Values Added Financial in Washington. Data shows that it happens to many retirees. About a third of retirees still have 100% or more of their initial savings remaining by their mid-80s, according to a recent study by the Employee Benefit Research Institute, a nonpartisan research group. "When you see so many people into their 80s still at 100%, you see people who are being way too conservative [with their spending]," said Craig Copeland, the director of wealth benefits research at EBRI. Read more CNBC personal finance coverage More workers are raiding their 401(k)s as average balances fall, Fidelity says Roth IRA owners may need a second retirement account to claim the Saver's Match Millions of people lose food stamp access as 'big beautiful bill' cuts take effect Trump Accounts create a 'legal backdoor' for Roth IRA wealth, tax attorney says CNBC's Financial Advisor 100: Best financial advisors, top firms ranked Of course, the opposite is true, too: "You also see some people with less than 20% [of their assets remaining] who are in the other situation: 'If I live five more years, I won't be able to do anything,'" Copeland said. About a fifth of people who entered retirement with more than $500,000 had less than 20% of their assets remaining by their mid-80s, according to EBRI's research. "This will be the foremost challenge in retirement: figuring out how to maximize retirement but still have a buffer at the end," Copeland said. The risk of underspending Vgaji...
A holder who started Friday, June 5, 2026 with $10,000 in ProShares Ultra Technology (NYSEARCA:ROM) ended the day with about $8,655. The fund opened at $161.98 and closed at $140.20, a single-session loss of 13.45%. Over the same five trading days, ROM gave back 11.8%, with the week starting at $158.95. Those numbers are what ... Why ROM Holders Watched $10,000 Evaporate to $8,655 When NVIDIA and ...
A holder who started Friday, June 5, 2026 with $10,000 in ProShares Ultra Technology (NYSEARCA:ROM) ended the day with about $8,655. The fund opened at $161.98 and closed at $140.20, a single-session loss of 13.45%. Over the same five trading days, ROM gave back 11.8%, with the week starting at $158.95. Those numbers are what ... Why ROM Holders Watched $10,000 Evaporate to $8,655 When NVIDIA and Broadcom Stumbled on Friday
BlackJack3D Shares of Coinbase Global ( COIN ), along with other major crypto-linked equities, pushed higher in premarket trading on Monday as a sharp rebound in Bitcoin prices injected fresh bullish sentiment back into the digital asset sector. Among gainers, Strategy ( MSTR ) +4%, Coinbase Global ( COIN ) +3.2%, Circle Internet Group ( CRCL ) +3.7%, Galaxy Digital ( GLXY ) +2.9%, Bullish ( BLSH ...
BlackJack3D Shares of Coinbase Global ( COIN ), along with other major crypto-linked equities, pushed higher in premarket trading on Monday as a sharp rebound in Bitcoin prices injected fresh bullish sentiment back into the digital asset sector. Among gainers, Strategy ( MSTR ) +4%, Coinbase Global ( COIN ) +3.2%, Circle Internet Group ( CRCL ) +3.7%, Galaxy Digital ( GLXY ) +2.9%, Bullish ( BLSH ) +2%, Robinhood Markets ( HOOD ) +2.2%, MARA Holdings ( MARA ) +2.9%, Hut 8 ( HUT ) +4.2%, and Iren ( IREN ) +3.7%. Bitcoin rose as much as 3.8% to nearly $64,200 on Monday before easing to around $63,400 in early New York trading, while Ether gained up to 5.6% to about $1,720. Bitcoin steadied after dropping below the key threshold of $60,000, as Strategy ( MSTR ) Chairman Michael Saylor hinted at further purchases of the token. Saylor also attributed Bitcoin's ( BTC-USD ) recent selloff to a shift of investor capital into AI rather than any deterioration in the cryptocurrency's long-term fundamentals. However, the sustainability of the bounce is in question as spot ETF flows show institutions have been actively selling into this dip. This starkly contrasts with February, when they eased off selling as prices approached the same long-term moving average, as per a CoinDesk report. Some analysts said the selloff is likely to deepen to mid-$50,000, or even lower, if the average gives away. "If the mid-$50Ks fail to hold, the next backstop is the $48K–$52K range. At these prices, older legacy mining rigs begin generating negative daily net revenue," Jean-David Péquignot, the chief commercial officer at leading crypto options exchange Deribit, told CoinDesk. "A drop to this level forces inefficient miners to unplug, prompting natural supply-side capitulation and a downward reset in network difficulty. Historically, miner capitulation phases align with cyclical bottoms," Péquignot said. More on Coinbase, Hut 8 Mining, etc. BTC: Why Bitcoin May Be Bottoming Now, Levels To Watch ...
10am: Semiconductors drive Nasdaq higher at open US tech stocks have led a Wall Street rebound in early Monday trading, with a sharp recovery in semiconductor names the key after they had been to the fore in Friday's heavy sell-off. The Nasdaq leapt 1.5% initially before this gain softened...
10am: Semiconductors drive Nasdaq higher at open US tech stocks have led a Wall Street rebound in early Monday trading, with a sharp recovery in semiconductor names the key after they had been to the fore in Friday's heavy sell-off. The Nasdaq leapt 1.5% initially before this gain softened...
Seaport Therapeutics, Inc. press release ( SPTX ): Q1 GAAP EPS of -$10.34. Cash, cash equivalents, and investments totaled $212.6 million as of March 31, 2026. Subsequent to March 31, 2026, Seaport completed its IPO, in which the Company raised gross proceeds of an additional $260.0 million, before deducting underwriting discounts, commissions, and other offering expenses. Seaport expects its curr...
Seaport Therapeutics, Inc. press release ( SPTX ): Q1 GAAP EPS of -$10.34. Cash, cash equivalents, and investments totaled $212.6 million as of March 31, 2026. Subsequent to March 31, 2026, Seaport completed its IPO, in which the Company raised gross proceeds of an additional $260.0 million, before deducting underwriting discounts, commissions, and other offering expenses. Seaport expects its current cash, cash equivalents, and investments to support its current operating plans into 2029. Net loss was $25.4 million for the first quarter of 2026, as compared to a net loss of $13.1 million for the first quarter of 2025. More on Seaport Therapeutics, Inc. Seaport Therapeutics Pursues IPO On Positive Trial Results Hemab, Seaport surge as clinical-stage biotechs make trading debuts Seaport, Hemab price upsized IPOs eyeing $550M in proceeds Historical earnings data for Seaport Therapeutics, Inc. Financial information for Seaport Therapeutics, Inc.
Cerebras ( CBRS ) rebounded on Monday, gaining 5% in premarket trading as Wall Street started coverage on the newly public chipmaker. Some firms said the company has “unique” capabilities that the competition can't fill. Shares were priced at $185 in the blockbuster offering that raised $5.55B and opened at $350. They have subsequently given up much of that gain. Here's what a sample of Wall Stree...
Cerebras ( CBRS ) rebounded on Monday, gaining 5% in premarket trading as Wall Street started coverage on the newly public chipmaker. Some firms said the company has “unique” capabilities that the competition can't fill. Shares were priced at $185 in the blockbuster offering that raised $5.55B and opened at $350. They have subsequently given up much of that gain. Here's what a sample of Wall Street firms had to say about Cerebras. Morgan Stanley (Overweight, $250 price target) “We view Cerebras as one of the most differentiated AI infrastructure companies, built around the industry's only commercially deployed wafer-scale processor,” Morgan Stanley analyst Joseph Moore wrote in a note to clients. “As AI workloads become increasingly reasoning-intensive, demand for fast, low-latency inference is growing rapidly. Supported by a large contracted backlog and a 750MW committed capacity agreement, we believe Cerebras is well positioned to capture this opportunity. This is a unique chance to invest in an AI processor company with a first-mover advantage against NVIDIA, and offers substantial upside as the category evolves.” UBS (Buy, $300 price target) “The Cerebras Wafer-Scale Engine (“WSE”) is the world's largest compute chip and offers performance advantage over GPUs on a subset of fast inference applications that address a premium segment of the inference market,” UBS analyst Timothy Arcuri wrote in a note to clients. “Importantly, CBRS has shown strong commercial momentum with a broad engagement as the only supplier currently shipping to OpenAI under a pre-payment, a growing inference collaboration with Amazon, and a number of additional potential engagements. Our PT is based on what we think is a conservative set of assumptions around the OpenAI rollout with Amazon adding optionality in out- years. Because we see CBRS eventually evolving into more of a hardware supplier, our $300 PT is based on 10x EV/Sales applied to C29 $11B Sales with our multiple driven by key ha...
More on FuelCell Energy FuelCell Energy: The Company That Wants To Become The Next Bloom Energy FuelCell Energy: Too Much Promise, Not Enough Proof FuelCell Energy Non-GAAP EPS of -$0.53 misses by $0.10, revenue of $35.59M misses by $4.92M Quant snapshot: United Natural Foods, Designer Brands lead top-rated names as MIND Technology, BARK lag Seeking Alpha’s Quant Rating on FuelCell Energy
More on FuelCell Energy FuelCell Energy: The Company That Wants To Become The Next Bloom Energy FuelCell Energy: Too Much Promise, Not Enough Proof FuelCell Energy Non-GAAP EPS of -$0.53 misses by $0.10, revenue of $35.59M misses by $4.92M Quant snapshot: United Natural Foods, Designer Brands lead top-rated names as MIND Technology, BARK lag Seeking Alpha’s Quant Rating on FuelCell Energy
SoFi (NASDAQ: SOFI) has fallen more than 40% so far in 2026, but the business posted record results in the first quarter. CEO Anthony Noto has been very vocal about some of the fintech's opportunities, and here are five quotes in particular investors need to hear. *Stock prices used were the morning prices of June 3, 2026. The video was published on June 4, 2026. Continue reading
SoFi (NASDAQ: SOFI) has fallen more than 40% so far in 2026, but the business posted record results in the first quarter. CEO Anthony Noto has been very vocal about some of the fintech's opportunities, and here are five quotes in particular investors need to hear. *Stock prices used were the morning prices of June 3, 2026. The video was published on June 4, 2026. Continue reading